Oseltamivir (tamiflu) induced depressive episode in a female adolescent.
Oseltamivir was developed for prophylactic and therapeutic use against influenza, specifically targeting the viral enzyme's highly-conserved active site. In recent years, there have been case reports of neuropsychiatric events during or after oseltamivir treatment, in Japan and other countries. However, a search of the literature revealed no such cases in South Korea. We present the case of a 15-year-old female adolescent diagnosed with depressive episode after taking oseltamivir. Oseltamivir is generally well tolerated. Its most frequent adverse effects include nausea and vomiting, diarrhea, and abdominal pain. In influenza patients taking oseltamivir, neuropsychiatric adverse events include delirium, behavioral disturbance, suicide, delusion, panic attack, convulsion, depressed mood, loss of consciousness, etc. Reportedly, such neuropsychiatric adverse events were more common in children than in adults and generally occurred within 48 hours of administration. Here, we report a retrospective review case of an oseltamivir-related neuropsychiatric event in a female adolescent in South Korea.
Department of Psychiatry, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Sungho
S
Chung
Yoo Sook
YS
Joung
Am J Psychiatry. 2010 Mar;167(3):350
20194491
Drug Metab Dispos. 2009 Feb;37(2):315-21
19029202
Drugs. 2001;61(2):263-83
11270942
Nature. 2007 Mar 22;446(7134):358-9
17377552
Pediatr Infect Dis J. 2001 Feb;20(2):127-33
11224828
Pediatr Infect Dis J. 2006 Jun;25(6):572
16732168
Neurosci Lett. 2007 Oct 9;426(1):54-8
17884292
Drugs. 1999 Nov;58(5):851-60; discussion 861-2
10595865
Neurosci Lett. 2008 Jun 13;438(1):67-9
18457919
Epidemiology. 2009 Jul;20(4):619-21
19367165
Int J Clin Pract. 2009 Apr;63(4):596-605
19335705
Drug Saf. 2008;31(12):1097-114
19026027
JAMA. 1999 Oct 6;282(13):1240-6
10517426
Nurse Pract. 2009 Feb;34(2):40-4
19155886
Eur J Pharmacol. 2010 Feb 25;628(1-3):6-10
19917275
Can Fam Physician. 2009 Dec;55(12):1199-201
20008597
Lancet. 2000 May 27;355(9218):1845-50
10866439
Drug Saf. 2003;26(11):787-801
12908848